Literature DB >> 19309055

The pharmacological management of skeletal-related events from metastatic tumors.

Anna Hitron1, Val Adams.   

Abstract

Bone is one of the most common sites of metastatic disease from cancer, affecting around 400,000 patients each year. Skeletal-related events (SRE) include hypercalcemia, fractures, spinal cord compression or severe bone pain and may occur as a complication of metastasis. Bisphosphonate therapy is crucial in the prevention and treatment of SREs; zoledronic acid and pamidronate have both been shown to significantly reduce the development of SREs. Other agents such as corticosteroids and analgesics are also used in symptomatic management. The use of these agents in conjunction with radiation and surgery can help to improve patient outcomes.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19309055     DOI: 10.3928/01477447-20090301-13

Source DB:  PubMed          Journal:  Orthopedics        ISSN: 0147-7447            Impact factor:   1.390


  5 in total

Review 1.  Clinical efficacy of denosumab versus bisphosphonates for the prevention of bone complications: implications for nursing.

Authors:  Cynthia Campbell-Baird; Stacey Harrelson; Georgette Frey; Arun Balakumaran
Journal:  Support Care Cancer       Date:  2015-08-23       Impact factor: 3.603

2.  Automated detection of sclerotic metastases in the thoracolumbar spine at CT.

Authors:  Joseph E Burns; Jianhua Yao; Tatjana S Wiese; Hector E Muñoz; Elizabeth C Jones; Ronald M Summers
Journal:  Radiology       Date:  2013-02-28       Impact factor: 11.105

Review 3.  Bisphosphonates in the treatment of patients with lung cancer and metastatic bone disease: a systematic review and meta-analysis.

Authors:  Maria A Lopez-Olivo; Nimit A Shah; Greg Pratt; Jan M Risser; Elaine Symanski; Maria E Suarez-Almazor
Journal:  Support Care Cancer       Date:  2012-09-07       Impact factor: 3.603

Review 4.  Patient-reported outcome instruments used to assess pain and functioning in studies of bisphosphonate treatment for bone metastases.

Authors:  Louis S Matza; Lesley J Fallowfield; Karen C Chung; Brooke M Currie; Kate Van Brunt; Donald L Patrick
Journal:  Support Care Cancer       Date:  2012-04       Impact factor: 3.603

5.  Ibandronate to treat skeletal-related events and bone pain in metastatic bone disease or multiple myeloma: a meta-analysis of randomised clinical trials.

Authors:  Chun-Jing Geng; Qian Liang; Jian-Hong Zhong; Min Zhu; Fan-Ying Meng; Ning Wu; Rui Liang; Bin-Yi Yuan
Journal:  BMJ Open       Date:  2015-06-02       Impact factor: 2.692

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.